e-ISSN 2147-2475

Hzl Arama




COVID-19 Pnmonisinde Youn Bakm nitesi ncesinde Favipiravir'in Etkinlii [Respir Case Rep]
Respir Case Rep. 2020; 9(3): 99-103 | DOI: 10.5505/respircase.2020.09216

COVID-19 Pnmonisinde Youn Bakm nitesi ncesinde Favipiravir'in Etkinlii

nder ztrk1, Volkan Balan1, Onur Kaya2, Esra Nurlu Temel2, Onur nal2, Veysel Atilla Ayyldz3, Mmtaz Cem irin4, Fevzye Burcu irin5, Gul Ruhsar Yilmaz2, Fusun Zeynep Akcam2, Mnire akr1, Ahmet Akkaya1
1Sleyman Demirel niversitesi, Tp Fakltesi, Gs Hastalklar Anabilim Dal, Isparta Trkiye
2Sleyman Demirel niversitesi, Tp Fakltesi, Enfeksiyon Hastalklar Anabilim Dal, Isparta, Trkiye
3Sleyman Demirel niversitesi, Tp Fakltesi, Radyoloji Anabilim Dal, Isparta, Trkiye
4Sleyman Demirel niversitesi, Tp Fakltesi, Klinik Mikrobiyoloji Anabilim Dal, Isparta, Trkiye
5Sleyman Demirel niversitesi, Tp Fakltesi, Klinik Biyokimya Anabilim Dal, Isparta, Turkiye

Aralk 2019'da Wuhan ehrinde ortaya kmasndan bu yana, koronavirs hastal (COVID-19) in'e hzla yayld. COVID-19 enfeksiyonuna bal yksek oranda hastaneye yat grlmesine ramen, spesifik bir tedavi bildirilmemitir. Bu balamda antiviral tedavi seimi snrldr. Japonya'da influenza iin onaylanan Favipiravir, RNA'ya baml RNA polimeraz (RdRP) hedefleyen ilalardan biridir. zellikle orta iddetteki COVID-19 olgularnda ate, ksrk dispnesi ve oksijen tedavisi veya noninvazif mekanik ventilasyon ihtiyacn nemli lde azaltt bilinmektedir. Bu yazda, hastalar youn bakm nitesine kabul etmeden nce klinik durumlar ktleen ve favipiravir ile takip edilerek iyileen drt olguyu sunduk.

Anahtar Kelimeler: SARS-CoV-2 (COVID-19), antiviral tedavi, favipiravir.

Effectiveness of Favipiravir prior to Admission to the Intensive Care Unit in COVID-19 Pneumonia

nder ztrk1, Volkan Balan1, Onur Kaya2, Esra Nurlu Temel2, Onur nal2, Veysel Atilla Ayyldz3, Mmtaz Cem irin4, Fevzye Burcu irin5, Gul Ruhsar Yilmaz2, Fusun Zeynep Akcam2, Mnire akr1, Ahmet Akkaya1
1Department of Chest Diseases, Faculty of Medicine, Sleyman Demirel University, Isparta, Turkey
2Department of Infection Diseases, Faculty of Medicine, Sleyman Demirel University, Isparta, Turkey
3Department of Radiology, Faculty of Medicine, Sleyman Demirel University, Isparta Turkey
4Department of Medical Microbiology, Faculty of Medicine, Sleyman Demirel University, Isparta, Turkey
5Department of Medical Biochemistry, Faculty of Medicine, Sleyman Demirel University, Isparta, Turkey

After emerging in Wuhan city in December 2019, the coronavirus disease 2019 (COVID-19) rapidly spread throughout China. Although high rates of hospitalization are seen with COVID-19, no specific treatment has been reported, and the choice of antiviral therapies is limited. Favipiravir, approved in Japan for influenza, is one of the drugs that targets RNA-dependent RNA polymerase (RdRP). It significantly decreases the duration of fever, cough dyspnea, and the need of oxygen therapy or noninvasive mechanical ventilation, especially in moderate COVID-19 cases. In the current paper we presented four cases with worsening clinical conditions and the development of hypoxia who were treated with Favipiravir before being admitted to the intensive care unit, and who recovered from the disease.

Keywords: SARS-CoV-2 (COVID-19), antiviral treatment, favipiravir.

Olgunun Tomografi Kesitleri




nder ztrk, Volkan Balan, Onur Kaya, Esra Nurlu Temel, Onur nal, Veysel Atilla Ayyldz, Mmtaz Cem irin, Fevzye Burcu irin, Gul Ruhsar Yilmaz, Fusun Zeynep Akcam, Mnire akr, Ahmet Akkaya. Effectiveness of Favipiravir prior to Admission to the Intensive Care Unit in COVID-19 Pneumonia. Respir Case Rep. 2020; 9(3): 99-103

Sorumlu Yazar: nder ztrk, Trkiye
LookUs & Online Makale